Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Accured Expenses (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Change in Accured Expenses for 8 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 2091.12% year-over-year to $3.4 million, compared with a TTM value of -$853000.0 through Sep 2025, down 304.27%, and an annual FY2024 reading of $7.2 million, up 345.83% over the prior year.
  • Change in Accured Expenses was $3.4 million for Q3 2025 at X4 Pharmaceuticals, up from $227000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.5 million in Q2 2023 and bottomed at -$7.8 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $433578.9, with a median of $627000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses soared 2540.3% in 2022, then plummeted 715.66% in 2025.
  • Year by year, Change in Accured Expenses stood at -$1.2 million in 2021, then surged by 304.59% to $2.5 million in 2022, then tumbled by 261.85% to -$4.0 million in 2023, then soared by 182.54% to $3.3 million in 2024, then grew by 0.84% to $3.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for XFOR at $3.4 million in Q3 2025, $227000.0 in Q2 2025, and -$7.8 million in Q1 2025.